Welcome to Coulter Partners Global (English)

24 August 2023

Coulter Partners places new Chief Business Officer at the Cell & Gene Therapy Catapult

Coulter Partners recently partnered with the Cell and Gene Therapy Catapult (CGT Catapult) and is pleased to announce the placement of Jeanette Evans as Chief Business Officer (CBO), taking over from Sharon Brownlow, with effect in August 2023.

CGT Catapult is an independent innovation and technology organisation committed to the advancement of cell and gene therapies, with a vision for a thriving industry delivering life-changing advanced therapies to the world.

As CBO of the organisation, Jeanette will be responsible for leading the organisation’s business development and legal teams, providing strategic leadership and supporting the teams as they work to establish and maintain collaborations with academics and industry.

Matthew Durdy, Chief Executive of the CGT Catapult, commented: “Jeanette’s extensive experience in business development and excellent track record in global transactions will be a welcome addition to our leadership team. We look forward to working with Jeanette as we continue to strengthen our partnerships and support for the advanced therapies sector. I would also like to thank Sharon Brownlow for all her work over these past few years, she has been vital to the growth and development of our work in the UK and we wish her all the best for the future.”

He added: “It has been a pleasure working with Coulter Partners on this key appointment for us. They understood our needs and ran a very smooth search process providing a good range of quality candidates to choose from.”

Jeanette Evans, Chief Business Officer elect of the CGT Catapult, added: “I am pleased to be joining the CGT Catapult and its experienced leadership team and I am looking forward to helping support its mission of growing and strengthening the advanced therapies industry in the UK. The dedication of the team at the CGT Catapult and their drive to build relationships and collaborations across the advanced therapies sector is inspirational.

Jeanette is a senior business development executive with over 25 years' experience in the pharmaceutical industry including working for leading companies such as AstraZeneca and Merck. She joins the CGT Catapult from Adaptimmune, where she most recently served as Vice President Business Development, leading the Business Development team. Through collaborations and partnerships with industry and academia, her team supported the advancement of Adaptimmune’s cell therapies for the treatment of patients with solid tumours. During her extensive career to date, Jeanette has had the opportunity to lead business development projects and transactions globally, across many therapeutic areas.

About the Cell and Gene Therapy Catapult
The Cell and Gene Therapy Catapult is an independent innovation and technology organisation committed to the advancement of cell and gene therapies with a vision of a thriving industry delivering life changing advanced therapies to the world. Its aim is to create powerful collaborations which overcome challenges to the advancement of the sector. The Cell and Gene Therapy Catapult works with Innovate UK.

For more information, please visit https://ct.catapult.org.uk/ or https://www.ukri.org/councils/innovate-uk/


A new version of Coulter Partners is available.